Statin Choice Around a Ritonavir-Boosted HIV Regimen
A single patient whose new hyperlipidemia diagnosis has an unusually large number of pharmacologically wrong answers before it has a right one.
T.A., a 39-year-old woman, has worked as an elementary school librarian for four years, a job she describes as the first stable thing in her adult life after a difficult stretch of years following her HIV diagnosis at twenty-eight — two failed regimens, a resistance mutation that narrowed her options, and finally, four years ago, a switch to a ritonavir-boosted darunavir regimen that has kept her viral load undetectable ever since. She has no intention of touching that regimen for any reason short of necessity, and this visit is the first time anyone has suggested a new medication might have to coexist with it.
Her father had a myocardial infarction at fifty-four, and her own lipid panel, drawn as part of a routine visit, came back with an LDL of 172 — high enough on its own, and higher still against that family history, to warrant treatment rather than lifestyle counseling alone. She is otherwise healthy: normal blood pressure, a non-smoker, a well-preserved CD4 count, no diabetes. The problem isn't her cardiovascular risk, which is ordinary and treatable. It's that most of the standard first answers to “which statin” carry real interactions with the one part of her regimen she cannot afford to disrupt.
The mechanical problem is specifically pharmacokinetic: ritonavir is a potent inhibitor of the cytochrome P450 3A4 enzyme system, the same pathway several statins depend on for clearance, and boosting her darunavir's blood levels comes at the cost of also boosting anything else that shares that pathway. Simvastatin and lovastatin are outright contraindicated in this combination; atorvastatin is only partially affected but still carries a real, dose-dependent increase in exposure, which is why it is capped near 20mg daily rather than banned. The genuinely useful subset are the statins cleared largely outside that system — though “outside CYP” is not the same as “no interaction,” since boosted regimens also disturb the hepatic uptake transporters some of those same statins depend on.
Choosing a statin around a boosted antiretroviral regimen
Pitavastatin is the cleanest answer here. It isn't meaningfully metabolized by the cytochrome P450 system, and no clinically significant interaction with ritonavir-boosted darunavir has been demonstrated — current HHS antiretroviral guidance lists it among the recommended statins and, unlike the others, requires no dose adjustment on a boosted regimen. The recommended dose is 4mg daily, which is what the trial evidence in people with HIV actually used. Everything else on that list comes with a ceiling attached; this one doesn't.
Pitavastatin is a defensible choice, but it isn't the only workable one — rosuvastatin is also minimally metabolized through CYP pathways, and it's a drug she's more likely to find on formulary without a prior authorization fight. I'd be precise about why it still needs a ceiling, though: its interaction with a boosted protease inhibitor is transporter-mediated rather than CYP-mediated, so it's present at every dose, not switched on above ten milligrams. Ten milligrams daily is the recommended cap, and at that dose the risk is acceptable.
I'd frame it as: don't reach for atorvastatin or simvastatin reflexively because they're familiar, not as “pitavastatin is the only safe option.” Two genuinely low-risk choices exist here, and access should be allowed to break the tie.
Whichever one we start, the more useful thing I can do today is confirm with her what her insurance will actually cover before she leaves, because a prior authorization delay on a first-choice statin often ends with someone quietly substituting atorvastatin at the pharmacy counter without looping back to us — and atorvastatin at an uncapped dose is exactly the interaction we're trying to avoid.
Started on pitavastatin 4mg daily, chosen specifically for its lack of meaningful interaction with her darunavir/ritonavir regimen and its guideline endorsement for exactly this situation. Repeat lipid panel planned at twelve weeks.
Rosuvastatin at 10mg or under is the agreed fallback — not atorvastatin at any dose.
Ezetimibe add-on is the next step discussed, rather than uptitrating a statin that already carries some interaction caution.
Nobody at the table disagreed about the destination — protecting a hard-won, currently undetectable regimen is not negotiable — the disagreement was only ever about which of two genuinely low-risk options should be tried first, and access, not pharmacology, settled it.